Chimovits Erez: insider trades.
Chimovits Erez reported 8 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 3 open-market purchases ($36.0M) and 0 sales, across 2 companies.
- Transactions
- 8
- Purchases (P)
- 3
- Sales (S)
- 0
- Companies
- 2
- Name as filed
- Chimovits Erez
Companies
| Company | Relationship | Transactions |
|---|---|---|
| ADARx Pharmaceuticals, Inc. (ADRX) | Director | 5 |
| Braveheart Bio, Inc. (BRVE) | Director, TenPercentOwner | 3 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 7,127,019 | — | 7,127,019 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 1,333,975 | — | 8,460,994 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 61,516 | $17 | 9,292,025 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 256,448 | — | 9,230,509 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 513,067 | — | 8,974,061 | Form 4 |
| 2026-08-07 | Braveheart Bio, Inc. | C | 9,132,420 | — | 10,235,159 | Form 4 |
| 2026-08-07 | Braveheart Bio, Inc. | P | 1,666,667 | $18 | 11,901,826 | Form 4 |
| 2026-08-07 | Braveheart Bio, Inc. | P | 273,333 | $18 | 273,333 | Form 4 |
Questions
What stock did Chimovits Erez buy or sell?
Chimovits Erez reported 8 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 3 open-market purchases ($36.0M) and 0 sales, across 2 companies.
Is Chimovits Erez the same person as other filers with this name?
This page covers SEC CIK 1706399 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/chimovits-erez-1706399.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.